Madrigal Pharmaceuticals | LinkedIn (original) (raw)

Pharmaceutical Manufacturing

Conshohocken, Pennsylvania 47,600 followers

Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.

About us

Madrigal (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis. For more information, visit www.madrigalpharma.com.

Industry

Pharmaceutical Manufacturing

Company size

201-500 employees

Headquarters

Conshohocken, Pennsylvania

Type

Public Company

Founded

2016

Specialties

Liver Disease, NASH, Metabolic Disease, and MASH

Locations

Employees at Madrigal Pharmaceuticals

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding